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Adeno-associated virus (AAV) vectors appear promising for use in gene therapy in cystic fibrosis (CF)
patients, yet many features of AAV-mediated gene transfer to airway epithelial cells are not well understood.
We compared the transduction efficiencies of AAV vectors and adenovirus (Ad) vectors in immortalized cell
lines from CF patients and in nasal epithelial primary cultures from normal humans and CF patients. Similar
dose-dependent relationships between the vector multiplicities of infection and the efficiencies of lacZ gene
transfer were observed. However, levels of transduction for both Ad and recombinant AAV (rAAV) were
significantly lower in the airway epithelial cell than in the control cell lines HeLa and HEK 293. Transduction
efficiencies differed among cultured epithelial cell types, with poorly differentiated cells transducing more
efficiently than well-differentiated cells. A time-dependent increase in gene expression was observed after
infection for both vectors. For Ad, but not for AAV, this increase was dependent on prolonged incubation of
cells with the vector. Furthermore, for rAAV (but not for rAd), the delay in maximal transduction could be
abrogated by wild-type Ad helper infection. Thus, although helper virus is not required for maximal trans-
duction, it increases the kinetics by which this is achieved. Expression of Ad E4 open reading frame 6 or
addition of either hydroxyurea or camptothecin resulted in increased AAV transduction, as previously dem-
onstrated for nonairway cells (albeit to lower final levels), suggesting that second-strand synthesis may not be
the sole cause of inefficient transduction. Finally, the efficiency of AAV-mediated ex vivo gene transfer to lung
cells was similar to that previously described for Ad vectors in that transduction was limited to regions of
epithelial injury and preferentially targeted basal-like cells. These studies address the primary factors influ-
encing rAAV infection of human airway cells and should impact successful gene delivery in CF patients.
Two DNA viruses, adeno-associated virus (AAV) and ade-
novirus (Ad), are currently being evaluated as vectors for hu-
man gene therapy of cystic fibrosis (CF) (9, 14, 15, 27–29, 41).
Outcomes of several human and preclinical studies of gene
therapy in CF patients, using Ad vectors, revealed that E1-
deleted Ad vectors need to resolve several obstacles in terms of
efficiency and safety (3, 17, 24, 40). At present, Ad vectors are
known to cause inflammation (3, 33, 39), to induce immune
responses (11, 36, 37, 39), and to be susceptible to recombina-
tion with endogenous virus (8, 10, 27). Fewer studies have been
carried out with AAV, but primary differences between AAV
and Ad vectors with regard to immune response and safety
have been noted (4). In addition, since wild-type virus is not
known to have the potential to cause disease in humans, re-
combination with endogenous virus seems less problematic
(20). Long-term expression of the CF transmembrane conduc-
tance regulator (CFTR) gene by AAV vectors has been de-
scribed for up to 180 days after vector administration to airway
epithelia of New Zealand White rabbits (15) and rhesus mon-
keys (4). Gene expression by first-generation Ad vectors in
airway epithelia has been transient in vivo. Such comparisons
support the further characterization of AAV vectors for use in
gene therapy in CF patients (2, 25).
Since a common observation with the use of Ad vectors in
primary airway cells has been inefficient transduction, we ini-
tiated a study to measure the requirements for AAV-mediated
gene transfer. Recently it has been shown that an immediate-
early event—namely, second-strand DNA synthesis—can be
rate limiting in the absence of Ad coinfection (12, 13). These
studies suggest that the limiting step in our ability to score gene
transduction in some cell types is not internalization of the
virus but rather the synthesis of a transcriptionally active dou-
ble-stranded version of the AAV genome. This genomic con-
version and the subsequent expression of the recombinant
reporter or therapeutic gene are greatly facilitated by expres-
sion of the Ad E4 open reading frame 6 (ORF6) protein (12,
13). Interestingly, the phenomenon elicited by the Ad E4
ORF6 protein can be reproduced to different degrees in re-
combinant AAV (rAAV)-infected cells by exposure of the cells
to heat shock or genotoxic reagents (12). It is assumed that Ad
E4 ORF6 and genotoxic and physical stresses are acting
through a common mechanism and that their effects are linked
to the induction of the host cell DNA repair machinery rather
than the cell cycle (12, 13). However, the precise mechanism
for the increase in AAV transduction has not been defined.
The impact of these findings on the use of AAV vectors for
gene therapy in CF patients is unclear. However, it is apparent
that rAAV vector transduction in some cultured cells can be
improved dramatically by physical and chemical manipulations
(1, 12, 13, 30), which suggests that similar reagents could be
coupled with current AAV vector strategies to enhance the
delivery of genes to the airway epithelia of human CF patients.
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Thus, one goal of this study was to determine the importance
of second-strand synthesis to AAV-mediated gene delivery to
the airway epithelium. Factors influencing the transduction
efficiency of AAV vectors relevant to the airway epithelium of
CF patients were compared to those of first-generation Ad
vectors. AAV and Ad vectors were used to deliver the lacZ
reporter gene to primary cultures of airway epithelial cells as
well as a spectrum of poorly differentiated (CF/T43 cells) and
well-differentiated (CFT1 cells) airway epithelial cell lines. We
observed low transduction efficiencies in these cells when using
these vectors, suggesting the existence of a potential barrier to
effective gene delivery in vivo.
Finally, we tested the efficiency of rAAV vectors for in vivo
gene transfer in human airways, using freshly excised human
tracheal specimens from normal humans and CF patients as a
model for the well-differentiated columnar epithelia and in-
jured epithelia characteristic of these individuals. Our results
support previous Ad vector studies demonstrating that basal-
like cell types, not columnar cell types, are preferentially trans-
duced by AAV vectors and that areas of transduction are
limited to regions of epithelial injury.
MATERIALS AND METHODS
Viruses and recombinant viral vectors. rAAV vectors were prepared in human
HEK 293 cells as previously described (26, 31, 34). Vectors were purified by
double CsCl gradient ultracentrifugation, dialyzed into 10 mM Tris-HCl–150
mM NaCl–10% glycerol, and stored at 220°C until used for infection of airway
epithelial cells. Vector titers, depicted as transducing units (TU) per milliliter,
were determined on Ad-infected HeLa cells by staining for b-galactosidase
activity (32). This procedure typically produced vector lots with titers of 108 to
109 TU/ml. The ratio of TU to the genome-based particle number was approx-
imately 1:100. The AAV vector lots were not heat inactivated, since this AAV
vector preparation method produces AAV free of wild-type Ad.
The Ad vector AdCMVbgal was used in this study. This vector encodes a
cytoplasmic b-galactosidase gene driven by the cytomegalovirus promoter-en-
hancer (9, 37). Ad vectors were propagated in HEK 293 cells, purified by CsCl
gradient ultracentrifugation, and stored at 220°C until use. Vectors titers were
determined on HeLa cells by staining for b-galactosidase activity. These titers
ranged from 2 3 1011 to 2 3 1012 TU/ml. The ratio of TU to the number of viral
particles (as determined by measuring the optical density at 260 nm) was ap-
proximately 1:20.
Wild-type Ad dl309 (23) was used to enhance AAV transduction. The Ad
mutants dl366* (19) (designated Ad E42) and E4dl ORF1–4 (21) (designated Ad
E42 ORF61 6/71) have been described previously. These mutants were used in
the studies of the helper function in AAV-mediated gene transfer in human
airway cells.
Ad was inactivated with long-wave UV irradiation in the presence of the DNA
intercalator psolaren (5). In brief, samples of Ad were added to a freshly pre-
pared 8-methoxypsoralen solution (0.33 mg/ml; Sigma) and, while on ice, exposed
to a 366-nm UV light source (model UVL-56; UVP Inc., Upland, Calif.) for 30
min. Following UV irradiation, the virus was purified by gel filtration (G-50
Sephadex; Boehringer Mannheim Corp., Indianapolis, Ind.) into phosphate-
buffered saline (PBS) containing 3% (vol/vol) glycerol.
Cell culture. Human nasal epithelial cells were isolated from nasal polyps of
CF patients and from turbinates of normal subjects and cultured as described in
detail elsewhere (35). All procedures were approved by the University of North
Carolina committee for the rights of human subjects. The cells were fed on
alternate days with serum-free, hormone-supplemented F-12 medium (supple-
ments included insulin [5 mg/ml], endothelial cell growth supplement [3.7 mg/ml],
epidermal growth factor [25 ng/ml], triiodothyroxine [3 3 1028 M], hydrocorti-
sone [1026 M], transferrin [5 mg/ml], and cholera toxin [10 ng/ml], plus penicillin
and streptomycin) (35).
Two immortalized airway epithelial cell lines from CF patients were also used
in this study. CF/T43 cells were developed from the nasal epithelium of a
homozygous DF508 CF patient and transformed with the simian virus 40 (SV40)
T antigen (22). CFT1 cells were derived from the tracheal epithelium of a
homozygous DF508 CF patient and transformed with the E6 and E7 genes of
human papillomavirus (38). All experiments using CF/T43 cells or CFT1 cells
were performed on a single clone, between passages 20 and 30. The cells were fed
on alternate days with serum-free, hormone-supplemented F-12 medium.
FIG. 1. Efficiency of AAVbgal-mediated gene transfer to human airway ep-
ithelial cells. Values are presented as means 6 standard errors of the means (n 5
5). Cells were infected for 1 h at 37°C, and the transduction efficiencies were
determined by histochemical staining for b-galactosidase activity 2 days after
infection, as described in Materials and Methods.
FIG. 2. The transduction efficiencies of AAV and Ad vectors in primary
cultures of human airway epithelial cells (A), CF/T43 cells (B), and CFT1 cells
(C). Values are presented as means 6 standard errors of the means (n 5 3).
Experimental conditions were the same as described in the legend to Fig. 1 and
are detailed in Materials and Methods.
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Transduction of human airway epithelial cells. Primary human nasal epithelial
cells or immortalized airway epithelial cell lines from CF patients were plated at
a density of 3 3 104 cells per well in 24-well dishes (Costar, Cambridge, Mass.)
and allowed to attach for 16 h, and then nonadherent cells were removed by
gentle washing with PBS. Two days after plating, the total number of cells per
dish was approximately 1 3 104 to 3 3 104. AAV vector (AAVbgal) or Ad vector
(AdCMVbgal) was added to the dishes at various multiplicities of infection
(MOIs) in 0.3 ml of medium. After incubation for various periods of time at 37°C
in air plus 5% CO2, the cells were washed with PBS and then fed with fresh,
hormone-supplemented F-12 medium. Control groups were exposed to 0.3 ml of
vehicle (F-12 medium) alone for comparable time periods and washed as de-
scribed above.
Two days after infection, the transduction efficiency was calculated by deter-
mining the percentage of b-galactosidase-expressing cells by histochemical stain-
ing (32). To assess the time course of transgene expression, staining was per-
formed at 1, 2, 3, 5, 7, and 10 days after vector exposure. All experiments were
performed at least in triplicate, and a minimum of 500 cells/well were counted to
determine the percentage of transduced cells.
Effect of Ad on AAV transduction. Two days after being plated, airway cells
were incubated with AAV or Ad vector and then exposed to Ad dl309 for 1 h at
37°C. Forty-eight hours later, the transduction efficiency was determined as
described above.
To elucidate the role of Ad in AAVbgal transduction of airway cells from CF
patients, these cells were exposed to AAV vector at different MOIs for 1 h in the
presence of either Ad dl309, UV- and psoralen-inactivated Ad dl309, Ad dl366*
(Ad E42), or E4dl ORF1–4 (Ad E42 ORF61 6/71) (100 particles/cell). The cells
were then washed with PBS and fed with fresh, hormone-supplemented F-12
medium. Two days later, transduction efficiencies were determined by staining
for b-galactosidase activity as described above.
Transduction of human tracheal explants with AAV. Freshly excised human
tracheal tissue (n 5 3 [CF patients] or 4 [normal subjects]) was obtained from
lung transplant CF patients and normal donors. Tracheal tissue was cut into
0.25-cm2 samples and exposed to 20 ml of a solution containing 108 TU (1010
genome-based particles) of AAVbgal vector/ml (MOI, ca. 1) for 30 min in the
presence or absence of Ad dl309 (100 particles/cell). Tracheal specimens were
then rinsed with PBS, incubated for 48 h at 37°C, fixed with 0.5% glutaraldehyde
in PBS, and stained for b-galactosidase activity. The tissue was postfixed with
OmniFixII (Aaron Medical Industries, St. Petersburg, Fla.), embedded in paraf-
fin, sectioned, and counterstained with hematoxylin plus eosin.
RESULTS
AAV transduction in airway cells of CF patients and normal
subjects. We first tested the transduction efficiency of rAAV by
infecting immortalized airway-specific cell lines and scoring for
vector transduction by measuring lacZ expression. The trans-
duction efficiency of the AAV vector increased in a dose-
dependent manner in all cell types (Fig. 1). There was no
FIG. 3. Effect of the presence of Ad on transduction of AAVbgal. (A) Air-
way epithelial cells infected with AAV or Ad vector, alone or with Ad dl309.
Values are presented as means 6 standard errors of the means (n 5 3). Airway
cells were infected with AAVbgal vector (100 TU/cell; 104 particles/cell) or
AdCMVbgal vector (100 TU/cell; 2 3 103 particles/cell) in the presence or
absence of Ad dl309 (100 IU/cell) for 1 h. Two days later, the transduction
efficiencies were determined by staining for b-galactosidase activity as described
in Materials and Methods. (B) The relative effect of Ad on AAVbgal transduc-
tion of HEK 293 cells, HeLa cells, and human airway epithelial cells. Levels of
transduction in the presence of Ad are shown relative to the level of transduction
in the absence of Ad, which has been assigned a value of 1. Airway cells were
infected with the AAVbgal vector (100 TU/cell; 104 particles/cell) or the
AdCMVbgal vector (100 TU/cell; 2 3 103 particles/cell) in the presence or
absence of Ad dl309 (100 IU/cell) as described for panel A. To allow for
increased transduction in the presence of Ad, HEK 293 and HeLa cells were
infected with 0.1 particle of AAVbgal vector or 0.5 particle of AdCMVbgal per
cell in the presence or absence of Ad dl309 (50 particles/cell).
FIG. 4. Relationship between Ad dose and enhancement of AAVbgal trans-
duction in primary cultures of human airway epithelial cells (A), CF/T43 cells
(B), and CFT1 cells (C). Cells were infected for 1 h at 37°C, and the transduction
efficiencies were determined by histochemical staining for b-galactosidase activ-
ity 24 h later. Each value is presented as the mean 6 the standard error of the
mean (n 5 3).
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difference in the transduction efficiency in primary nasal epi-
thelial cells of CF patients versus those of normal subjects
throughout the range of vector doses used (Fig. 1). The trans-
duction efficiencies in the CF/T43 and CFT1 cell lines, how-
ever, differed dramatically. At the same MOI of AAV vector,
the transduction efficiency in CF/T43 cells was approximately
4- to 10-fold higher than that in the CFT1 cell line (Fig. 1).
Ad and AAV vectors transduce airway epithelial cells with
similar efficiencies. We next compared the transduction effi-
ciencies of AAV, lacZ, and Ad lacZ vectors in various airway-
specific cell lines. The dose-effect relationships of vector MOI
and transduction efficiency of airway cells from CF patients
were remarkably similar for the AAV and Ad vectors (Fig. 2).
The Ad vector was slightly more efficient in transduction of
primary cells than was the AAV vector at the highest MOI
(Fig. 2A). However, the efficiency of Ad vector transduction of
the CF/T43 cell line was somewhat less than that of the AAV
vector (Fig. 2B). In CFT1 cells there was no difference in the
transduction efficiencies of the AAV and Ad vectors (Fig. 2C).
These results suggest that transduction efficiencies can vary,
depending on the specific cell line and vector being tested.
Enhancement of rAAV but not rAd transduction by subse-
quent wild-type Ad infection. Previous work has demonstrated
a rate-limiting step in rAAV-mediated transduction that can
be alleviated by helper Ad coinfection (12, 13). To test this
premise in airway epithelial cells, coinfections with rAAV and
wild-type Ad were performed. AAV-mediated gene transfer to
airway epithelial cells was enhanced in the presence of Ad
dl309, whereas Ad-mediated gene transfer was unaffected by
Ad dl309 (Fig. 3). In the presence of Ad, the AAV vector was
considerably more efficient at transducing airway cells than was
the Ad vector (Fig. 3A). We next compared the enhancement
seen in airway cells after Ad coinfection to the reported ob-
servations in HeLa and 293 cells (12, 13). At 100 IU of Ad
dl309 per cell, AAV transduction increased only two- to seven-
fold, whereas at 2 IU of Ad dl309 per cell, AAV transduction
of HEK 293 and HeLa cells increased by several orders of
magnitude (Fig. 3B). The effect of Ad on AAV transduction
was dose dependent for each CF cell type analyzed, although
the magnitude of the effect differed among the cell lines (Fig.
4).
The effect of Ad on AAV transduction was abolished by
UV-psoralen inactivation of Ad gene expression (Fig. 5). In
addition, an Ad mutant lacking the E4 region (E42 Ad) was
unable to enhance AAV transduction (Fig. 5). However, a
partially deleted Ad mutant, lacking E4 ORF1–4 but contain-
ing ORF6 and ORF6/7 (Ad E42 ORF61 6/71), maintained
the ability to increase AAV vector transduction similarly to
that of Ad dl309 (Fig. 5), supporting previous published ob-
servations for the role of Ad gene expression in rAAV trans-
duction (12, 13).
Prolonged incubation increases transduction of cultured
human airway epithelial cells. We tested another variable,
involving extended vector exposure, for its effect on vector
transduction. Both the AAV and Ad vectors exhibited a rela-
tionship between the length of exposure of airway epithelial
cells and the efficiency of gene transfer (Fig. 6). All of the cell
FIG. 5. Transduction of airway epithelial cells with rAAV in the presence of different Ad mutants. Values are presented as means 6 standard errors of the means
(n 5 3). Vector AAVbgal (104 particles/cell) was administered to cells for 1 h in the presence or absence of Ad dl309, UV- and psoralen-inactivated Ad dl309, E42
Ad, or E42 Ad ORF61 6/71 (each at 1,000 particles/cells). At 24 h after infection, the cells were stained for b-galactosidase activity as described in Materials and
Methods.
FIG. 6. Effect of prolonged vector incubation time on the transduction of
primary cultures of human airway epithelial cells (A), CF/T43 cells (B), and
CFT1 cells (C) by AAVbgal. Values are presented as means 6 standard errors
of the means (n 5 3). Cells were incubated with the vector for the indicated
period of time, washed, cultured for an additional 48 h in the absence of vector,
and stained for b-galactosidase activity to determine the efficiency of transduc-
tion.
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types showed similar requirements of prolonged exposure to
achieve maximal transduction. No additional effect was de-
tected when incubation times were extended longer than 24 h
(data not shown). However, since transduction was determined
48 h after each of the different exposure periods (1, 6, 12, or
24 h), the cells from each experimental group were ultimately
maintained in culture for different periods of time (2 to 3 days).
Thus, we sought to determine if the duration of exposure or
the duration of time in culture was responsible for the increase
in transduction. Cells were infected for 1 h, washed free of
unbound vector, and then monitored for different lengths of
time in culture prior to staining for LacZ to access the amount
of gene transfer. For AAV vectors, the percentage of LacZ-
expressing cells increased with increased time in culture (Fig.
7). The highest levels of transduction were seen 3 to 5 days
after infection of primary airway cells and CFT1 cells (Fig. 7A
and C) and 3 days after infection of CF/T43 cells (Fig. 7B).
These results are similar to those of the previous experiment,
in which the highest level of transduction occurred following a
24-h incubation period and 48 h of growth in culture, i.e., 3
days after initial vector administration.
For the Ad vector, maximal transduction was observed at the
earliest time points (Fig. 7). The percentage of transduced cells
decreased over time in culture and was nearly zero at 10 days
postinfection (Fig. 5). Because of these differences in the effect
of time on expression from Ad and AAV vectors, there was a
significant difference in the efficiencies of transduction of air-
way cells by AAV and Ad vectors at three or more days fol-
lowing vector administration. The maximal effect of time in
culture on transduction was approximately three- to sevenfold.
Interestingly, this was similar to the increase in transduction
observed during coinfection with Ad.
To investigate the relationship between the effect of the
presence of Ad and the duration of incubation on AAV trans-
duction, airway epithelial cells were infected with AAV for a
short period of time and then infected with Ad at various times
following the initial vector infection. It was determined that
either time or Ad coinfection could be used to increase AAV
transduction, but the effects were not additive (Fig. 8). When
exposure to the AAV vector was limited to 1 h, nearly the same
level of transduction could be achieved with a 1-h incubation in
the presence of Ad as could be achieved with a 24-h incubation
in the absence of Ad (Fig. 8). Ad was able to increase AAV
transduction at the early time points. However, given time,
transduction increased to the same level on its own and Ad no
longer had an effect. UV- and psoralen-inactivated Ad or E42
Ad was unable to alleviate the need for a prolonged incubation
FIG. 7. Activation of rAAV vector over time in culture. Primary human
airway epithelial cells from CF patients (A), CF/T43 cells (B), and CFT1 cells (C)
were infected with AAVbgal for 1 h at 37°C. Transduction efficiencies were
determined on the indicated days postinfection by staining for b-galactosidase
activity as described in Materials and Methods. Values are presented as means 6
standard errors of the means (n 5 3).
FIG. 8. Effect of Ad on AAVbgal transduction of primary airway cells from
CF patients (A), CF/T43 cells (B), or CFT1 cells (C) at various times postinfec-
tion. Cells were initially infected with AAVbgal for 1 h at 37°C, washed, and then
exposed to Ad dl309, UV- and psoralen-inactivated Ad dl309, E42 Ad, or E42
ORF61 6/71 Ad for 1 h at the indicated times post-rAAV infection. All cells
were stained for LacZ activity 48 h following rAAV infection as described in the
text. Values represent the means of data from triplicate experiments.
8908 TERAMOTO ET AL. J. VIROL.
time, whereas the E42 ORF61 6/71 virus functioned similarly
to Ad dl309 (Fig. 8). Since the effects of time and the presence
of Ad on AAV transduction of airway epithelial cells were not
additive and could substitute for one another, it is assumed
that they are acting in a similar manner; i.e., both result in the
accumulation of functional genomes.
As mentioned above, a number of other agents have also
been shown to increase AAV-mediated gene transduction.
Both camptothesin and hydroxyurea were able to increase
AAV transduction of airway epithelial cells (Fig. 9). However,
by 3 days after vector delivery, these agents were no longer able
to increase gene transduction (Fig. 9). These results support
the above-mentioned interpretation of the conversion of sin-
gled-stranded AAV genomes to doubled-stranded templates
capable of gene expression over time or enhanced by the ad-
dition of genetic (Ad coinfection) or chemical (hydroxyurea)
stimuli.
Transduction of human tracheal explants with rAAV is lim-
ited to basal-like cells. In the absence of Ad, three of eight
freshly exercised human tracheal specimens infected with
rAAV exhibited lacZ gene expression; however, the transduc-
tion efficiency, as assessed by determining the percentage of
LacZ-expressing cells, was less than 0.1% (data not shown).
Whereas basal-like cells were transduced in relatively ample
quantities by the AAV vector (Fig. 10C and D), well-differen-
tiated, ciliated columnar cells were not transduced by this
vector (Fig. 10A and B). In the presence of Ad, LacZ-positive
cells were found in one of three specimens. Because transduc-
tion efficiency, as assessed by determination of LacZ-positive
cells, was less than 0.1%, there was no obvious enhancement of
AAV transduction in the presence of Ad (data not shown).
Further, features of cell tropism (columnar cells versus basal
cells) of AAV vectors were not affected by coadministration of
Ad.
DISCUSSION
Several studies reporting successful CFTR gene expression
in airway epithelia by the use of AAV vectors have suggested
that AAV may be a promising vector for gene therapy of CF
airway disease (4, 14, 15). However, compared with the de-
tailed descriptions of gene expression in airway epithelia in
animal models, the features of AAV vectors in human airway
epithelial cells have not been fully elucidated.
As a part of our initial characterization of AAV vectors in
human airway epithelial cells, we tested whether the CF phe-
notype affected the efficiency of AAV vector-mediated gene
transfer. The dose-dependent relationships between the
amount of AAV vector applied and the percentage of trans-
duced cells were similar in primary cultures of airway epithelial
cells derived from both normal and CF subjects (Fig. 1). These
results indicate that the absence of functional cell surface
CFTR activity does not effect the efficiency of AAV gene
transfer. Previous studies of AAV-mediated gene transfer to
human airway epithelial cells have been performed with im-
mortalized cell lines from CF patients, such as IB3 (16). Be-
cause IB3 cells have been transformed by a chimeric virus (Ad
type 12 [Ad12]/SV40), it was not clear if the efficiency of vector
transduction in these cells would hold true for AAV transduc-
tion of primary, untransformed human airway epithelial cells
from CF patients. Therefore, we performed a comprehensive
study comparing the transduction efficiencies of AAV vectors
in primary cultures of airway epithelial cells from normal sub-
jects and CF patients and two additional immortalized CF cell
lines (Fig. 1). Interestingly, the ability of AAV to transduce
these cells varied by severalfold. While the CF/T43 cell line was
more efficiently transduced by an AAV vector than were pri-
mary airway cells, the CFT1 cell line was considerably less-
efficiently transduced than the primary cells. These observa-
tions with the CF/T43 cell line are in agreement with the data
of Halbert and coworkers (18), who reported that the trans-
duction efficiency of AAV vectors was 10 to 60 times higher in
immortalized human cells than in primary cells. However, our
results with the CFT1 cell line suggest that the transduction
efficiency of airway epithelial cells cannot be predicted simply
as a function of immortalization. In addition, it should be
noted that these results may be influenced by the clonal isola-
tion of these cell lines and may not be related to the mecha-
nism of immortalization.
Several factors may be pertinent to these observations. It is
possible that the differences in transduction efficiency reflect
influences of the immortalizing genes (e.g., the SV40 T-antigen
gene for cell line CF/T43 and the human papillomavirus E6/E7
gene for cell line CFT1) (22, 38) on the molecular conversion
of the viral genome or on the expression of the reporter gene.
Differences in the transduction efficiencies of Ad vectors have
been observed as a feature of cell differentiation (6, 7). CFT1
cells are more highly differentiated than CF/T43 cells, suggest-
ing that differentiation status may directly or indirectly affect
AAV transduction of airway cells. Another explanation could
be related to the differences in the growth rates of these cell
lines. CFT1 cells proliferate at a rate 50% slower than that of
FIG. 9. Effect of Ad and DNA-damaging agents on rAAV transduction of
airway epithelial cell lines. (A) The indicated cell lines were infected with
AAVbgal (1,000 particles/cell) for 1 h at 37°C and then treated with the indicated
agents and stained for b-galactosidase activity following 48 h in culture, as
described in Materials and Methods. (B) The cells were cultured for 48 h after
infection, prior to treatment with the indicated agents, and then cultured for an
additional 48 h prior to assessment of transduction.
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CF/T43 cells. Regardless of the mechanism, the evaluation of
each of these CF cell lines will undoubtedly aid in our under-
standing of AAV-mediated gene transfer to CF patient air-
ways. Since the more highly differentiated CFT1 cells are less
efficiently transduced by AAV vectors than are the less-differ-
entiated CF/T43 cells, the CFT1 cell line may be a better
predictor of AAV transduction efficiency in differentiated air-
way epithelia of CF patients in vivo, an observation which has
held true for Ad vectors (17).
AAV and Ad vectors were equally efficient at transferring
genes to airway epithelial cells of CF patients (Fig. 2) unless
AAV-mediated transduction was aided by the coadministra-
tion of Ad (Fig. 3). In the presence of Ad, AAV was more
efficient at transducing airway epithelial cells than was Ad
alone. However, the overall efficiency of transduction of airway
cells was quite low, and the magnitude of the increase in
transduction caused by Ad coinfection was much lower in the
airway epithelial cells than that observed in the HEK 293 or
HeLa cell line. Previously we have shown that Ad is able to
enhance AAV transduction by overcoming a block in the con-
version of single-stranded viral genomes into transcriptionally
active, double-stranded molecules (12). A key issue relates to
whether Ad-enhanced AAV transduction of airway cells is due
to an increase in AAV uptake or to increased second-strand
synthesis. In immortalized fibroblast cells, we have shown that
the enhancement of AAV transduction by Ad is due to Ad E4
ORF6 gene expression (12). Several lines of evidence suggest
that the Ad helper effect in the airway epithelium is also based
on Ad E4 ORF6 gene expression. First, UV-psoralen treat-
ment of Ad, which has been shown to inactivate gene expres-
sion but preserve entry functions (5), abolishes the effect of Ad
on AAV transduction (Fig. 5 and 8). Second, the deletion of
the E4 region from the Ad genome abrogates the helper effect.
However, an Ad mutant with a partially deleted E4 region,
containing only ORF6 and ORF6/7, retained the helper effect
(Fig. 5 and 8). These data indicate that the E4 genes, specifi-
cally those in ORF6 or ORF6/7, are responsible for the en-
hancement of AAV transduction in airway epithelial cells of
CF patients in a manner similar to that previously described for
immortalized fibroblast cell lines (12, 13). The only difference
is that the magnitude of the effect is considerably less in airway
epithelial cells than in the previously studied cell lines. Trans-
duction of HeLa and HEK 293 cells with AAV vectors in-
creased 1,000-fold in the presence of Ad. Using the same
rAAV vectors and helper Ad, transduction of airway epithelial
cells increased only two- to sevenfold.
Since airway epithelial cells are less efficiently infected with
Ad (Fig. 2 and 3A), it is possible that the effect of Ad on AAV
transduction was limited by the inefficiency of the Ad infection.
For this reason, we attempted to increase AAV transduction in
the absence of Ad by treating AAV-infected cells with geno-
toxic agents. These compounds have previously been shown to
increase AAV transduction in a manner analogous to Ad E4
ORF6 gene expression (1, 12, 30). Hydroxyurea and campto-
thesin were both able to increase rAAV transduction (Fig. 9).
The maximal effect on AAV transduction with these agents
was similar to that achieved with Ad (103 particles/cells), sug-
gesting that Ad infection was not limiting in these determina-
tions. Thus, agents which presumably act by increasing AAV
second-strand DNA synthesis have only a small effect on vector
transduction of human airway epithelial cells. This suggests the
possibility that transduction of these cells is blocked at another
FIG. 10. Histological sections of freshly excised tissue from CF patients. Human tracheal specimens were cut into 0.25-cm2 samples and infected with AAVbgal for
30 min. At 48 h after exposure, specimens were fixed with 0.5% glutaraldehyde and stained for b-galactosidase activity as described in Materials and Methods. The
sections were counterstained with hematoxylin and eosin. Regions of the epithelium containing well-differentiated columnar cells were not transduced by AAVbgal (A
and B), whereas areas of the epithelium that were injured and had exposed cuboidal, basal-like cells were moderately well transduced by this vector (C and D).
Magnifications: A, C, and D, 3250; B, 31,000.
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level. However, it should be noted that histochemical staining
for the detection of b-galactosidase activity may not be very
sensitive in these cell types, and many more cells could have
been positive than were scored by this method. Testing more-
sensitive reporter genes, such as green fluorescent protein, may
help resolve this potential concern.
Both AAV and Ad vectors exhibited incubation time-depen-
dent increases in gene transduction (Fig. 6). These observa-
tions initially suggested that the nature of AAV vector trans-
duction of airway cells was similar to that of Ad vectors.
However, the need for a long AAV vector incubation time
could be eliminated by increasing the time in culture prior to
accessing gene transduction (Fig. 7) or by coinfecting with
wild-type Ad (Fig. 8), whereas expression from Ad vectors
declined steadily over time in culture and wild-type Ad had no
effect on the time course of rAd transduction. This suggests
that the factors governing effective transduction by each of
these vectors are different. It seems likely that Ad is blocked at
the level of vector entry (hence the requirement for prolonged
exposure to the host cells) and that AAV may be blocked at a
secondary intracellular event (hence the need for Ad coinfec-
tion or additional time in culture). It is intriguing that the block
to efficient transduction alleviated by Ad is absent at 5 days
postinfection. Presumably, airway epithelial cells are capable
of supporting second-strand synthesis at a low level in the
absence of Ad, such that AAV genomes become transcription-
ally active slowly over time.
Finally, we tested the efficiency of gene transfer by AAV
vectors to freshly excised human tracheal specimens. Typically,
basal-like cells, rather than columnar ciliated cells, were trans-
duced by AAV vectors. This phenomenon is very similar to
Ad-mediated gene transfer to human airway tissue (17). There
was no evidence of enhancement of AAV-mediated gene
transfer to the human tracheal explants by Ad. However, this is
not surprising due to the poor infectivity of ciliated epithelial
cells by Ad (17). These preliminary results suggest that AAV
vector transduction of the airway epithelium may be cell type
dependent in a manner analogous to Ad vector transduction.
Therefore, the efficiency of AAV transduction of human air-
way epithelia in vivo may not be predicted by the results of in
vitro AAV transduction of cultured human primary cells,
which exhibit a basal-cell-like phenotype. For this reason, the
two CF airway epithelial cell lines used in this study, which
exhibit very different states of differentiation (poorly differen-
tiated [CF/T43] versus more highly differentiated [CFT1]), may
be useful reagents for investigation of the rate-limiting steps in
efficient transduction of airways of CF patients with recombi-
nant AAV vectors. Our results of transductions of primary
airway tissue also illustrate the need to perform parallel exper-
iments in vivo in order to establish a complete analysis of
vector behavior for efficient gene delivery.
ACKNOWLEDGMENTS
S. Teramoto and J. S. Bartlett contributed equally to this work.
This research was aided by NIH grants HL 51818 and HL 42384 to
R.C.B. and 51880 to R.J.S. and by CFF grants R026 to R.C.B. and
MARZLU96PO to J.S.B.
REFERENCES
1. Alexander, I. E., D. W. Russell, and A. D. Miller. 1994. DNA-damaging
agents greatly increase the transduction of nondividing cells by adeno-asso-
ciated virus vectors. J. Virol. 68:8282–8287.
2. Bartlett, J. S., K. B. Quattrocchi, and R. J. Samulski. 1995. The development
of adeno-associated virus as a vector for cancer gene therapy, p. 27–40. In
R. E. Sobol and K. J. Scanlon (ed.), The Internet book of gene therapy:
cancer therapeutics. Appleton & Lange, Stamford, Conn.
3. Brody, S. L., and R. G. Crystal. 1994. Adenovirus-mediated in vivo gene
transfer. Ann. N. Y. Acad. Sci. 31:90–101.
4. Conrad, C. K., S. S. Allen, S. A. Afione, T. C. Reynolds, S. E. Beck, M.
Fee-Maki, X. Barrazza-Ortiz, R. Adams, F. B. Askin, B. J. Carter, W. B.
Guggino, and T. R. Flotte. 1996. Safety of single-dose administration of an
adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther.
3:658–668.
5. Cotten, M., E. Wagner, K. Zatloukal, S. Phillips, D. T. Curiel, and M. L.
Birnstiel. 1992. High-efficiency receptor-mediated delivery of small and large
(48 kilobase) gene constructs using the endosome-disruption activity of de-
fective or chemically inactivated adenovirus particles. Proc. Natl. Acad. Sci.
USA 89:6094–6098.
6. Croyle, M. A., E. Walter, S. Janich, B. J. Roessler, and G. L. Amidon. 1998.
Role of integrin expression in adenovirus-mediated gene delivery to the
intestinal epithelium. Hum. Gene Ther. 9:561–573.
7. Dupuit, F., J. M. Zahm, D. Pierrot, S. Brezillion, N. Bonnet, J. L. Imler, A.
Pavirani, and E. Puchelle. 1995. Regenerating cells in human airway surface
epithelium represent preferential targets for recombinant adenovirus. Hum.
Gene Ther. 6:1185–1193.
8. Eissa, N. T., C. S. Chu, C. Danel, and R. G. Crystal. 1994. Evaluation of the
respiratory epithelium of normals and individuals with cystic fibrosis for the
presence of adenovirus E1a sequences relevant to the use of E1a-adenovirus
vectors for gene therapy for the respiratory manifestations of cystic fibrosis.
Hum. Gene Ther. 5:1105–1114.
9. Engelhardt, J. F., R. H. Simon, Y. Yang, M. Zepeda, S. Weber-Pendleton, B.
Doranz, M. Grossman, and J. M. Wilson. 1993. Adenovirus-mediated trans-
fer of the CFTR gene to lung of nonhuman primates: biological efficacy
study. Hum. Gene Ther. 4:759–769.
10. Engelhardt, J. F., Y. Yang, L. D. Stratford-Perricaudet, E. D. Allen, K.
Kozarsky, M. Perricaudet, J. R. Yankaskas, and J. Wilson. 1993. Direct gene
transfer of human CFTR into human bronchial epithelia of xenografts with
E1-deleted adenoviruses. Nat. Genet. 4:27–34.
11. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2A
in recombinant adenoviruses improves transgene persistence and decreases
inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:6196–
6200.
12. Ferrari, F. K., T. Samulski, T. Shenk, and R. J. Samulski. 1996. Second-
strand synthesis is a rate-limiting step for efficient transduction by recombi-
nant adeno-associated virus vectors. J. Virol. 70:3227–3234.
13. Fisher, K. J., G.-P. Gao, M. D. Weitzman, R. DeMatteo, J. F. Burda, and
J. M. Wilson. 1996. Transduction with recombinant adeno-associated virus
for gene therapy is limited by leading-strand synthesis. J. Virol. 70:520–532.
14. Flotte, T. R., S. A. Afione, C. Conrad, S. A. McGrath, R. Solow, H. Oka, P. L.
Zeitlin, W. B. Guggino, and B. J. Carter. 1993. Expression of the cystic
fibrosis transmembrane conductance regulator from a novel adeno-associ-
ated virus promoter. J. Biol. Chem. 268:3781–3790.
15. Flotte, T. R., S. A. Afione, C. Conrad, S. A. McGrath, R. Solow, H. Oka, P. L.
Zeitlin, W. B. Guggino, and B. J. Carter. 1993. Stable in vivo expression of
the cystic fibrosis transmembrane regulator with an adeno-associated virus
vector. Proc. Natl. Acad. Sci. USA 90:10613–10617.
16. Flotte, T. R., R. Solow, R. A. Owens, S. Afione, P. L. Zeitlin, and B. J. Carter.
1992. Gene expression from adeno-associated virus vectors in airway epithe-
lial cells. Am. J. Respir. Cell Mol. Biol. 7:349–356.
17. Grubb, B. R., R. J. Pickles, H. Ye, J. R. Yankaskas, R. N. Vick, J. F.
Engelhardt, J. M. Wilson, L. G. Johnson, and R. C. Boucher. 1994. Ineffi-
cient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of
mice and humans. Nature 371:802–806.
18. Halbert, C. L., I. E. Alexander, G. M. Wolgamot, and A. D. Miller. 1995.
Adeno-associated virus vectors transduce primary cells much less efficiently
than immortalized cells. J. Virol. 69:1473–1479.
19. Halbert, D. H., J. R. Cutt, and T. Shenk. 1985. Adenovirus early region 4
encodes functions required for efficient DNA replication, late gene expres-
sion, and host cell shutoff. J. Virol. 56:250–257.
20. Hoggan, M. D., N. R. Blacklow, and W. P. Rowe. 1966. Studies of small DNA
viruses found in various adenovirus preparations: physical, biological, and
immunological characteristics. Proc. Natl. Acad. Sci. USA 55:1457–1471.
21. Huang, M.-M., and P. Hearing. 1989. Adenovirus early region 4 encodes two
gene products with redundant effects in lytic infection. J. Virol. 63:2605–
2615.
22. Jetten, A. M., J. R. Yankaskas, M. J. Stutts, N. J. Willumsen, and R. C.
Boucher. 1989. Persistence of abnormal chloride conductance regulation in
transformed cystic fibrosis epithelia. Science 244:1472–1475.
23. Jones, N., and T. Shenk. 1979. Isolation of adenovirus type 5 host range
deletion mutants defective for transformation of rat embryo cells. Cell 17:
683–689.
24. Knowles, M. R., K. W. Hohnekker, Z. Zhou, J. C. Olsen, T. L. Noah, P.-C.
Hu, M. W. Leigh, J. F. Engelhardt, L. J. Edwards, J. R. Jones, M. Gross-
mann, J. M. Wilson, L. G. Johnson, and R. C. Boucher. 1995. A controlled
study of transfer by adenoviral-vector-mediated gene transfer in the nasal
epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333:823–831.
25. Kotin, R. M. 1994. Prospects for the use of adeno-associated virus as a vector
for human gene therapy. Hum. Gene Ther. 5:793–801.
26. Li, J., R. J. Samulski, and X. Xiao. 1997. Role for highly regulated rep gene
VOL. 72, 1998 AAV-MEDIATED GENE TRANSFER TO AIRWAY EPITHELIAL CELLS 8911
expression in adeno-associated virus vector production. J. Virol. 71:5236–
5243.
27. Rich, D. P., L. A. Couture, L. M. Cardoza, V. M. Guiggio, D. Armentano,
P. C. Espino, K. Hehir, M. J. Welsh, A. E. Smith, and R. J. Gregory. 1993.
Development and analysis of recombinant adenoviruses for gene therapy of
cystic fibrosis. Hum. Gene Ther. 4:461–476.
28. Rosenfeld, M. A., C. S. Chu, P. Seth, C. Danel, T. Banks, K. Yoneyama, K.
Yoshimura, and R. G. Crystal. 1994. Gene transfer to freshly isolated human
respiratory epithelial cells in vitro using a replication-deficient adenovirus
containing the human cystic fibrosis transmembrane conductance regulator
cDNA. Hum. Gene Ther. 5:331–342.
29. Rosenfeld, M. A., K. Yoshimura, B. C. Trapnell, K. Yoneyama, E. R.
Rosenthal, W. Dalemans, M. Fukayama, J. Bargon, L. E. Stier, L. Stratford-
Perricaudet, et al. 1992. In vivo transfer of the human cystic fibrosis trans-
membrane conductance regulator gene to the airway epithelium. Cell 68:
143–155.
30. Russell, D. W., A. D. Miller, and I. E. Alexander. 1995. DNA synthesis and
topoisomerase inhibitors increase transduction by adeno-associated virus
vectors. Proc. Natl. Acad. Sci. USA 92:5719–5723.
31. Samulski, R. J., L.-S. Chang, and T. Shenk. 1989. Helper-free stocks of
recombinant adeno-associated viruses: normal integration does not require
viral gene expression. J. Virol. 63:3822–3828.
32. Sanes, J. R., J. L. R. Rubenstein, and J. F. Nicolas. 1986. Use of a recom-
binant retrovirus to study post-implantation cell lineage in mouse embryos.
EMBO J. 5:3133–3142.
33. Simon, R. H., J. F. Engelhardt, Y. Yang, M. Zepeda, S. W. Pendelton, M.
Grossman, and J. M. Wilson. 1993. Adenovirus-mediated transfer of the
CFTR gene to lung of nonhuman primates: toxicity study. Hum. Gene Ther.
4:821–836.
34. Snyder, R. O., X. Xiao, and R. J. Samulski. 1996. Production of recombinant
adeno-associated virus vectors, p. 12.1.1–12.2.23. In N. Dracopoli, J. Haines,
B. Krof, D. Moir, C. Seidman, and J. S. Seidman (ed.), Current protocols in
human genetics. John Wiley & Sons Ltd., New York, N.Y.
35. Wu, R., J. R. Yankaskas, E. Cheng, M. R. Knowles, and R. C. Boucher. 1985.
Growth and differentiation of human nasal epithelial cells in culture: serum-
free, hormone-supplemented medium and proteoglycan synthesis. Am. Rev.
Respir. Dis. 132:311–320.
36. Yang, Q., F. Chen, and J. P. Trempe. 1994. Characterization of cell lines that
inducibly express the adeno-associated virus Rep proteins. J. Virol. 68:4847–
4856.
37. Yang, Y., F. A. Nunes, K. Berencsi, E. Gönczöl, J. F. Engelhardt, and J. M.
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